News on government policy and legislation impacting life science and diagnostics.
OIG will evaluate data to assess whether PAMA pricing results in market-based rates
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.
Genetic counselors and patient advocates say more people are refusing genetic testing because they're uncertain of how it will impact their insurance.
